| Want to jump right to here next time? Bookmark: www.canpku.org/education/treatments/pku |
PKU Treatments and Therapies in Canada
PKU treatment plans are individualized and guided by your metabolic clinic. This page provides a plain-language overview of therapies currently used in Canada, including medical nutrition and medications authorized by Health Canada. Not every option applies to every person with PKU.
Important: Always follow your clinic’s recommendations. Some treatments require responsiveness testing, age criteria, safety monitoring, staged dosing, and provincial coverage approval.
Canada check: Medication authorization and marketing status can change. If you want to confirm whether a medication is currently authorized and marketed in Canada, you can verify it in Health Canada’s Drug Product Database.
Jump to: Core therapies | Medical nutrition | Medications (authorized) | Hospital care | Research, trials, and what’s in the pipeline
Core therapies for PKU
For most people with PKU, treatment begins with a phenylalanine-restricted (Phe-restricted) diet and medical nutrition. These remain the foundation of care, even when medications are added.
Phe-restricted diet (foundational therapy)
PKU dietary therapy focuses on limiting phenylalanine while still providing enough protein and nutrients for growth, development, and overall health. Measuring systems (exchanges, grams, or total protein) and targets can differ by clinic.
Medical nutrition
Medical nutrition is considered a primary treatment for PKU and is used across the lifespan.
What medical nutrition can include
- Metabolic formula (Phe-free or low-Phe protein substitute)
- Low-protein specialty foods (coverage varies by province)
- Clinic-recommended supplementation when required
Related education: Nourish | Low Protein Meal Planning Tools
Medications authorized in Canada
The medications below are authorized by Health Canada for use in specific PKU populations. Eligibility, responsiveness testing, dosing approach, safety monitoring, and coverage can vary.
Sephience™ (sepiapterin)
Brand: Sephience™
Generic/medical name: sepiapterin
Plain-language note: Sephience is authorized in Canada for sepiapterin-responsive PKU and is used with a Phe-restricted diet. Your clinic will determine responsiveness and monitoring for your situation.
Generic/medical name: sepiapterin
Plain-language note: Sephience is authorized in Canada for sepiapterin-responsive PKU and is used with a Phe-restricted diet. Your clinic will determine responsiveness and monitoring for your situation.
Canada status: listed as Marketed in Health Canada’s portal (status date shown). See Sources below for verification links.
Palynziq® (pegvaliase)
Brand: Palynziq®
Generic/medical name: pegvaliase
Palynziq is authorized in Canada to reduce blood phenylalanine in patients with PKU aged 16 years and older who have inadequate blood phenylalanine control despite dietary management. Treatment typically involves staged dosing and close clinic monitoring.
Generic/medical name: pegvaliase
Palynziq is authorized in Canada to reduce blood phenylalanine in patients with PKU aged 16 years and older who have inadequate blood phenylalanine control despite dietary management. Treatment typically involves staged dosing and close clinic monitoring.
Coverage note: public/private coverage decisions vary by province/insurer and may include eligibility criteria.
Sapropterin (BH4 therapy): Kuvan® and authorized generics
Brand (originator): Kuvan®
Generic/medical name: sapropterin dihydrochloride
Sapropterin is authorized in Canada for individuals with BH4-responsive PKU. In responders, it may help lower blood phenylalanine levels and/or increase dietary tolerance. Your clinic may recommend a response trial and lab monitoring.
Generic/medical name: sapropterin dihydrochloride
Sapropterin is authorized in Canada for individuals with BH4-responsive PKU. In responders, it may help lower blood phenylalanine levels and/or increase dietary tolerance. Your clinic may recommend a response trial and lab monitoring.
Authorized generics: Some generic sapropterin products are also listed as marketed in Health Canada’s portal (example: REDDY-SAPROPTERIN). Brand availability can vary by province/plan and over time.
Hospital care and emergency planning
Some infants, children, or adults with PKU may need medical guidance during illness, poor intake, or other metabolic stress. Your clinic can provide a sick-day plan and an emergency letter (if appropriate) so that emergency teams understand your PKU management needs.
Tip: Ask your clinic if you have an emergency letter and whether it needs updating.
Research, trials, and what’s in the pipeline
Looking for research studies, registries, or clinical trials (including studies that may be recruiting)? We track current research and study opportunities on our dedicated page:
PKU Studies & Trials PKU Registry
Optional external resources:
Sources and references
- Health Canada – Drug Product Database (DPD): how to verify what is authorized in Canada
- Health Canada (DHPP) – SEPHIENCE (sepiapterin) product listing (status/marketing)
- Health Canada – Product Monograph: SEPHIENCE (sepiapterin)
- PTC Therapeutics (CNW) – announcement of Health Canada approval for SEPHIENCE (sepiapterin)
- Health Canada – Summary Basis of Decision: KUVAN (sapropterin dihydrochloride)
- Health Canada (DHPP) – REDDY-SAPROPTERIN (sapropterin) product listing (status/marketing)
- Health Canada – Summary Basis of Decision: PALYNZIQ (pegvaliase)
- CADTH (CDA-AMC) – reimbursement recommendation summary: pegvaliase (Palynziq)
External links are shared for education and support. CanPKU+ does not control external content. Always confirm medical guidance with your metabolic clinic.